scholarly journals Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes

2017 ◽  
Vol 9 (6) ◽  
pp. 499-507 ◽  
Author(s):  
Alaaeldin Bashier ◽  
Azza Abdulaziz Khalifa ◽  
Fauzia Rashid ◽  
Elamin Ibrahim Abdelgadir ◽  
Amina Adil Al Qaysi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycated Hemoglobin ◽  
Sglt2 Inhibitors ◽  
Efficacy And Safety

scholarly journals What Are The Benefits In The Association Of SGLT2 Inhibitors And Other Drugs?

10.3823/2540 ◽  
2017 ◽  
Vol 10 ◽  
Author(s):  
Deici Aparecida Gomes Rodrigues ◽  
Isabela Macêdo Alves ◽  
Isabelly De Oliveira Pinheiro ◽  
Élida Camilla Nunes Valões ◽  
Erich Pires Lisboa
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Glycated Hemoglobin ◽  
Postprandial Glucose ◽  
Sglt2 Inhibitors ◽  
Loss Reduction ◽  
Fat Reduction ◽  
Postprandial Glucose Level ◽  
Level Reduction

The SGLT2 inhibitors are a class of drugs that blocks the sodium-glucose co-transport, which is responsible for 90% of the nephron glucose. Objective: To show the benefits of the SGLT2 inhibitors in monotherapy and in association with other drugs. Results: The association of SGLT2 inhibitors and other drugs has shown several additional benefits after their interaction, including weight loss, reduction of body fat, reduction of triglycerides level, decrease of glycated hemoglobin, decrease in postprandial glucose level, reduction of arterial pressure, decrease of hypoglycemia risk and improvement of glucose metabolism. Therefore, this is a promising interaction for type 2 diabetes.

Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus

2012 ◽  
Vol 12 (3) ◽  
pp. 230-238 ◽  
Author(s):  
Muhammad A. Abdul-Ghani ◽  
Luke Norton ◽  
Ralph A. DeFronzo
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Sglt2 Inhibitors ◽  
Efficacy And Safety
Sign in / Sign up

Export Citation Format

Share Document